A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
• The subject voluntarily signs an informed consent form before any procedures related to the research start;
• At the time of screening, it met the 2006 psoriatic arthritis classification standard (CASPAR)；
• There is active PsA before randomization;
• Have active plaque psoriasis (at least one plaque skin lesion) at the time of screening, or have a history of plaque psoriasis;
• Participants who have previously been treated with csDMARDs and/or NSAIDs still have active psoriatic arthritis disease.